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Abstract Immunosuppression plays a pivotal role in
assisting tumors to evade immune destruction and pro-
moting tumor development. We hypothesized that genetic
variation in the immunosuppression pathway genes may be
implicated in breast cancer tumorigenesis. We included
42,510 female breast cancer cases and 40,577 controls of
European ancestry from 37 studies in the Breast Cancer
Association Consortium (2015) with available genotype
data for 3595 single nucleotide polymorphisms (SNPs) in
133 candidate genes. Associations between genotyped
SNPs and overall breast cancer risk, and secondarily
according to estrogen receptor (ER) status, were assessed
using multiple logistic regression models. Gene-level
associations were assessed based on principal component
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analysis. Gene expression analyses were conducted using
RNA sequencing level 3 data from The Cancer Genome
Atlas for 989 breast tumor samples and 113 matched nor-
mal tissue samples. SNP rs1905339 (A[G) in the STAT3
region was associated with an increased breast cancer risk
(per allele odds ratio 1.05, 95 % confidence interval
1.03–1.08; p value = 1.4 9 10-6). The association did not
differ significantly by ER status. On the gene level, in
addition to TGFBR2 and CCND1, IL5 and GM-CSF
showed the strongest associations with overall breast can-
cer risk (p value = 1.0 9 10-3 and 7.0 9 10-3, respec-
tively). Furthermore, STAT3 and IL5 but not GM-CSF were
differentially expressed between breast tumor tissue and
normal tissue (p value = 2.5 9 10-3, 4.5 9 10-4 and
0.63, respectively). Our data provide evidence that the
immunosuppression pathway genes STAT3, IL5, and GM-
CSF may be novel susceptibility loci for breast cancer in
women of European ancestry.
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Introduction
Breast cancer is the most frequent cancer among women
and the second leading cause of cancer-related death after
lung cancer in Europe. In addition to genetic variants with
high and moderate penetrance, more than 90 common
germline genetic variants contributing to breast cancer risk
have been identified, comprising about 37 % of the familial
relative risk of the disease (Michailidou et al. 2013, 2015).
This suggests that a substantial portion of inherited varia-
tion has not yet been identified. In addition, most of the
known common susceptibility variants reside in non-coding
regions and result in subtle regulation of gene expression.
The biological mechanisms through which genetic variants
exert their functions are still not entirely understood.
The ability to evade immune destruction has been
increasingly recognized as a key hallmark of tumors
(Hanahan and Weinberg 2011). Tumor cells may secrete
immunosuppressive factors like TGF-b which hampers
infiltrating cytotoxic T lymphocytes and natural killer cells
(Yang et al. 2010). Inflammatory cells like regulatory T
cells (Treg cells), a subset of CD4? T lymphocytes, as well
as myeloid-derived suppressor cells (MDSCs) may be
recruited into the tumor environment, which are actively
immunosuppressive (Lindau et al. 2013; Reisfeld 2013).
Higher prevalence of Treg cells has been found in various
cancers (Chang et al. 2010; Michel et al. 2008; Watanabe
et al. 2002), including breast cancer (Bates et al. 2006).
There is evidence that tumor infiltrating Treg cells endowed
with immunosuppressive potential are associated with
tumor progression and unfavorable prognosis, especially in
estrogen receptor (ER)-negative breast cancer (Bates et al.
2006; Kim et al. 2013; Liu et al. 2012a). In addition, infil-
trating MDSCs were also found in murine mammary tumor
models (Aliper et al. 2014; Gad et al. 2014), but their rel-
evance for breast cancer patients also in terms of prognosis
is not well-understood. Furthermore, previous association
studies have identified susceptibility alleles for breast can-
cer in two genes, TGFBR2 (transforming growth factor beta
receptor II) (Michailidou et al. 2013) and CCND1 (cyclin
D1) (French et al. 2013), which may be involved in immune
regulation in cancer patients (Gabrilovich and Nagaraj
2009; Krieg and Boyman 2009), including those with breast
cancer. We hypothesized that immunosuppression pathway
genes, particularly those relevant to Treg cell and MDSC
functions, may harbor further susceptibility variants asso-
ciated with breast cancer tumorigenesis, with a possible
differential association by ER status.
In this analysis, we investigated associations between
breast cancer risk and single nucleotide polymorphisms
(SNPs) in 133 candidate genes in the immunosuppression
pathway in individual level data from the Breast Cancer
Association Consortium (BCAC). We also assessed asso-
ciations with breast cancer risk at the gene and pathway
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levels. Furthermore, we used publicly available datasets
through the UCSC Genome Browser (2015) to examine the
putative genetic susceptibility loci for potential regulatory
function.
Materials and methods
Study participants
In this analysis, participants were restricted to 83,087
women of European ancestry from 37 case–control studies
participating in BCAC, including 42,510 invasive breast
cancer cases with stage I–III disease and 40,577 cancer-
free controls. Of all breast cancer patients, 26,094 were
known to have ER-positive disease and 6870 to have ER-
negative disease. Details of included studies are summa-
rized in Online Resource 1. All studies were approved by
the relevant ethics committees and all participants gave
informed consent (Michailidou et al. 2013).
Candidate gene selection
Candidate genes relevant to the Treg cell and MDSC
pathways were identified through a comprehensive litera-
ture review in PubMed (DeNardo et al. 2010; DeNardo and
Coussens 2007; Driessens et al. 2009; Gabrilovich and
Nagaraj 2009; Krieg and Boyman 2009; Mills 2004;
Ostrand-Rosenberg 2008; Poschke et al. 2011; Sakaguchi
et al. 2013; Sica et al. 2008; Wilczynski and Duechler
2010; Zitvogel et al. 2006; Zou 2005), using the search
terms ‘‘immunosuppression’’/‘‘immunosuppressive’’,
‘‘regulatory T cells’’/‘‘Treg cells’’/‘‘FOXP3? T cells’’,
‘‘myeloid derived suppressor cells’’/‘‘MDSCs’’, ‘‘im-
munosurveillance’’, and ‘‘tumor escape’’. The final candi-
date gene list included 133 immunosuppression-related
genes (Online Resource 2). SNPs within 50 kb upstream
and downstream of each gene were identified using Hap-
Map CEU genotype data (2015) and dbSNP 126.
SNP association analyses
For the BCAC studies, genotyping was carried out using a
custom Illumina iSelect array (iCOGS) designed for the
Collaborative Oncological Gene-Environment Study
(COGS) project (Michailidou et al. 2013). Of the 211,155
SNPs on the array, 4246 were located within 50 kb of the
selected candidate genes. Centralized quality control of
genotype data led to the exclusion of 651 SNPs. The
exclusion criteria included a call rate less than 95 % in all
samples genotyped with iCOGS, minor allele frequency
(MAF) less than 0.05 in all samples, evidence of deviation
from Hardy–Weinberg equilibrium (HWE) at p value
\10-7, and concordance in duplicate samples less than
98 % (Michailidou et al. 2013). A total of 3595 SNPs
passed all quality controls and was analyzed.
49 Department of Cancer Epidemiology, Clinical Cancer
Registry, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany
50 Unit of Molecular Bases of Genetic Risk and Genetic
Testing, Department of Preventive and Predictive Medicine,
Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere
Scientifico) Istituto Nazionale dei Tumori (INT), Milan, Italy
51 IFOM, Fondazione Istituto FIRC (Italian Foundation of
Cancer Research) di Oncologia Molecolare, Milan, Italy
52 Department of Laboratory Medicine and Pathology, Mayo
Clinic, Rochester, MN, USA
53 Cancer Epidemiology Centre, Cancer Council Victoria,
Melbourne, Australia
54 Department of Preventive Medicine, Keck School of
Medicine, University of Southern California, Los Angeles,
CA, USA
55 Genomics Center, Centre Hospitalier Universitaire de
Que´bec Research Center, Laval University, Que´bec City,
Canada
56 Department of Medicine, McGill University, Montreal,
Canada
57 Division of Clinical Epidemiology, Royal Victoria Hospital,
McGill University, Montreal, Canada
58 Department of Genetics, Institute for Cancer Research, Oslo
University Hospital Radiumhospitalet, Oslo, Norway
59 K.G. Jebsen Center for Breast Cancer Research, Institute of
Clinical Medicine, Faculty of Medicine, University of Oslo,
Oslo, Norway
60 Department of Clinical Molecular Biology, Oslo University
Hospital, University of Oslo, Oslo, Norway
61 Division of Epidemiology, Department of Medicine,
Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, TN, USA
62 Laboratory of Cancer Genetics and Tumor Biology,
Department of Clinical Chemistry and Biocenter Oulu,
University of Oulu, Oulu, Finland
63 Central Finland Hospital District, Jyva¨skyla¨ Central Hospital,
Jyva¨skyla¨, Finland
64 Department of Surgery, Oulu University Hospital, University
of Oulu, Oulu, Finland
65 Lunenfeld-Tanenbaum Research Institute of Mount Sinai
Hospital, Toronto, Canada
66 Department of Molecular Genetics, University of Toronto,
Toronto, Canada
67 Division of Genetics and Epidemiology, The Institute of
Cancer Research, London, UK
68 Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Rockville, MD, USA
140 Hum Genet (2016) 135:137–154
123
Per-allele associations with the number of minor alleles
were assessed using multiple logistic regression models,
adjusted for study, age (at diagnosis for cases or at
recruitment for controls) and nine principal components
(PCs) derived based on genotyped variants to account for
European population substructure. We assessed the asso-
ciations of SNPs with overall breast cancer risk as primary
analyses, and then restricted to ER-positive (26,094 cases
and 40,577 controls) and ER-negative subtypes (6870 cases
and 40,577 controls) as secondary analyses. Differences in
the associations between ER-positive and ER-negative
diseases were assessed by case-only analyses, using ER
status as the dependent variable. To determine the number
of ‘‘independent’’ SNPs for adjustment of multiple testing,
we applied the option ‘‘–indep-pairwise’’ in PLINK (Pur-
cell et al. 2007). SNPs were pruned by linkage disequi-
librium (LD) of r2\ 0.2 for a window size of 50 SNPs and
step size of 10 SNPs, yielding 689 ‘‘independent’’ SNPs.
The significance threshold using Bonferroni correction
corresponding to an alpha of 5 % was 7.3 9 10-5.
In order to identify more strongly associated variants,
genotypes were imputed for SNPs at the locus for which
strongest evidence of association was observed, via a two-
stage procedure involving SHAPEIT (Howie et al. 2012)
and IMPUTEv2 (Howie et al. 2009), using the 1000 Gen-
omes Project data as the reference panel (Abecasis et al.
2012). Details of the imputation procedure are described
elsewhere (Michailidou et al. 2015). Models assessing
associations with imputed SNPs were adjusted for 16 PCs
based on 1000 Genome imputed data to further improve
adjustment for population stratification. To determine
independent signals within imputed SNPs at STAT3, we ran
a stepwise forward multiple logistic regression model
including the most significant genotyped SNP rs1905339
and all imputed SNPs, adjusted for study, age and 16 PCs.
SNP association analyses and case-only analyses were
all conducted using SAS 9.3 (Cary, NC, USA). All tests
were two-sided.
For multiple associated SNPs located at the same gene, a
Microsoft Excel SNP tool created by Chen et al. (2009) and
the software HaploView 4.2 (Barrett et al. 2005) were used to
examine LD structure between these SNPs. To be able to
inspect LD structures and also for gene-level analyses, allele
dosages of imputed SNPs had to be converted into the most
probable genotypes. Therefore, we categorized the imputed
allele dosage between [0, 0.5] as homozygote of the refer-
ence allele, the value between [0.5, 1.5] as heterozygote, and
the value between [1.5, 2.0] as homozygote of the counted
allele. The regional association plot was generated using the
online tool LocusZoom (Pruim et al. 2010).
Gene-level and pathway association analyses
Gene-level associations were determined by a subset of
PCs, which were derived from a linear combination of
SNPs in each gene explaining 80 % of the variation in the
joint distribution of all relevant SNPs. Associations with
derived PCs were assessed within a logistic regression
framework (Biernacka et al. 2012), for overall breast can-
cer, ER-positive and ER-negative diseases, respectively.
Pathway association of the immunosuppression pathway
was assessed based on a global test of association by
combining the gene-level p values via the Gamma method
(Biernacka et al. 2012). For gene-level associations, asso-
ciations with p value\3.8 9 10-4 (Bonferroni correction)
were considered statistically significant. To gain empirical
p values for gene-level associations of TGFBR2 and
CCND1 as well as for the pathway association, a Monte
Carlo procedure was used with up to 1,000,000 random-
izations (Biernacka et al. 2012). An exact binomial test
based on the results of the single SNPs association analyses
was carried out to estimate enrichment of association in the
immunosuppression pathway. Gene-level and pathway
association analyses were carried out in R (version 3.1.1)
using the package ‘GSAgm’ version 1.0.
Haplotype analyses
To follow up the interesting gene associations observed,
haplotype analyses were performed to identify potential
susceptibility variants. Haplotype frequencies were deter-
mined with the use of the estimation maximization (EM)
algorithm (Long et al. 1995) implemented in PROC
HAPLOTYPE in SAS 9.3 (Cary, NC, USA). Haplotypes
with frequency more or equal than 1 % were examined and
the most common haplotype was used as the reference.
Rare haplotypes with frequency less than 1 % were
grouped into one category. Haplotype-specific odds ratios
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(ORs) and 95 % confidence intervals (CIs) were estimated
within a multiple logistic regression framework, adjusted
for the same covariates as in the single SNP association
analyses. Global p values for association of haplotypes
with breast cancer risk were computed using a likelihood
ratio test comparing models with and without haplotypes of
the gene of interest.
Gene expression analyses
In order to examine whether potential causative genes
influence RNA expression in breast tumor tissue, we
downloaded RNA sequence level 3 data from The Cancer
Genome Atlas (TCGA) (2015). We retrieved the
RNA expression level as the form of RNA-Seq by expec-
tation–maximization (RSEM) based on the Illumi-
naHiSeq_RNASeqV2 array. Gene expression differences in
RNA levels between 989 invasive breast cancer tissues and
113 matched normal tissues for four genes of interest
(STAT3, PTRF, IL5, and GM-CSF) were analyzed using a
two-sided Wilcoxon–Mann–Whiney test. In addition, data
from 183 breast tissues in the GTEx (V6) (2015) publically
available online databases were evaluated to obtain infor-
mation on whether the most interesting variants (rs1905339,
rs8074296, rs146170568, chr17:40607850:I and rs77942990)
were expression quantitative trait loci (eQTL) for any gene.
Also, GTEx was queried to obtain information on whether
the five variants were eQTL for STAT3 or PTRF.
Functional annotation
To investigate potential regulatory functions of interesting
polymorphisms, we used the Encyclopedia of DNA Ele-
ments (ENCODE) database through the UCSC Genome
Browser as well as Haploreg v4 (Ward and Kellis 2012).
Results
Selected characteristics of the study population are
described in Table 1. The controls and breast cancer
patients included in this study had comparable mean ref-
erence ages of 54.8 and 55.9 years and also the proportion
of postmenopausal women was similar (68 % in controls
and 69 % in breast cancer patients). The proportion of
women indicating a family history of breast cancer in first
degree relatives was as expected greater in breast cancer
patients (25 %) than in controls (12 %).
Single SNP associations
Excluding the known TGFBR2 and CCND1 breast cancer
susceptibility loci, the quantile–quantile (QQ) plot for
associations with overall breast cancer risk for the geno-
typed SNPs of the other candidate genes indicated deviation
from expected p values and thus evidence of further SNPs
associated with breast cancer risk (Online Resource 3).
Genetic associations with overall breast cancer risk for all
assessed 3595 SNPs are summarized in Online Resource 4.
Four independent genotyped SNPs (LD r2\ 0.3) were
significantly associated with breast cancer risk at p value
\7.3 9 10-5, accounting for the multiple comparisons
(Table 2). The four significant SNPs were located in or
near TGFBR2, STAT3 and CCND1. Since TGFBR2 and
Table 1 Characteristics of breast cancer cases and controls
Characteristic Controls Cases
No. % No. %
Total number 40,577 42,510
Age (mean, SD) 54.8 12.0 55.9 11.6
Family history of breast cancer
No 20,940 88 24,397 75
Yes 2829 12 7971 25
Unknown/missing 16,808 10,142
Menopausal status
Pre/perimenopausal 9174 32 9296 31
Postmenopausal 19,753 68 20,714 69
Unknown/missing 11,650 12,500
Estrogen receptor status
Negative 6870 21
Positive 26,094 79
Unknown/missing 9546
Progesterone receptor status
Negative 9299 33
Positive 19,017 67
Unknown/missing 14,194
Triple-negative cancer
No 13,675 84
Yes 2600 16
Unknown/missing 26,235
Stage
0 25 0.1
I 12,044 50
II 9711 40
III 1975 8
IV 496 2
Unknown/missing 18,259
Grade
Well differentiated 6125 21
Moderately differentiated 14,092 48
Poorly/un-differentiated 8937 31
Unknown/missing 13,356
SD standard deviation
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CCND1 have been identified as breast cancer susceptibility
loci in previous studies (French et al. 2013; Michailidou
et al. 2013; Rhie et al. 2013), we focused on the association
of the SNP at STAT3. The variant rs1905339 (A[G) at
STAT3 was positively associated with overall breast cancer
risk (per allele odds ratio (OR) 1.05, 95 % confidence
interval (CI) 1.03–1.08, p value = 1.4 9 10-6). It showed
similar associations with ER-positive and ER-negative
cancers (Online Resource 5). We did not observe further
SNPs that were significantly associated with ER-positive or
ER-negative disease (data not shown).
To identify additional susceptibility variants at STAT3,
we further investigated 707 SNPs that were well-imputed
(imputation accuracy r2[ 0.3) and with MAF [0.01
spanning a ±50 kb window around STAT3. Seven inde-
pendent signals at STAT3 were found through the stepwise
forward selection procedure. The genotyped SNP
rs1905339 was not selected. The imputed SNP rs8074296
(A[G), which was in high LD with rs1905339 (r2 = 0.99),
showed a comparable OR for the association with overall
breast cancer risk with a more extreme p value (per allele
OR 1.05, 95 % CI 1.03–1.08, p value = 8.6 9 10-7,
Table 3). A second imputed SNP rs146170568 (C[T),
associated with a per allele OR of 1.32 (95 % CI
1.16–1.50, p value = 2.1 9 10-5), was still strongly
associated at a p value of 3.2 9 10-4 after accounting for
rs8074296 (Table 3). None of the independently associated
imputed SNPs besides rs8074296 were correlated with
rs1905339 or with each other (r2 B 0.01, Fig. 1). As
rs8074296 and rs1905339 are located closer to PTRF than
to STAT3, we additionally analyzed data of 178 imputed
variants located within ±50 kb of PTRF. Associations of
most additional variants in the PTRF region with breast
cancer risk were attenuated in analyses conditioning on
rs8074296 (Table 4). The variants chr17:40607850:I and
rs77942990 still showed a strong association with breast
cancer risk (per allele OR 1.09, 95 % CI 1.04–1.15,
p value = 0.0005; and per allele OR 1.09, 95 % CI
1.04–1.15, p value = 0.0007, respectively). These two
variants were also not in LD with rs8074296 (r2 = 0.09
Table 2 TGFBR2, CCND1 and STAT3 SNPs associated with overall breast cancer risk in women of European ancestry after Bonferroni
correction (p value\7.3 9 10-5)
SNP Chr. Positiona Gene Minor allele MAF cases MAF controls Cases Controls OR (95 %CI)b p value
rs1431131 3 30,675,880 TGFBR2 A 0.37 0.36 42,508 40,574 1.06 (1.04–1.08) 2.6 9 10-8
rs11924422 3 30,677,484 TGFBR2 C 0.40 0.41 42,491 40,572 0.95 (0.94–0.97) 6.9 9 10-6
rs7177 11 69,466,115 CCND1 C 0.46 0.47 42,411 40,496 0.96 (0.94–0.98) 2.7 9 10-5
rs1905339 17 40,582,296 STAT3 G 0.34 0.33 42,504 40,576 1.05 (1.03–1.08) 1.4 9 10-6
SNP single nucleotide polymorphism, Chr. chromosome, MAF minor allele frequency, OR odds ratio, CI confidence interval, TGFBR2 trans-
forming growth factor beta receptor II, CCND1 cyclin D1, STAT3 signal transducer and activator of transcription 3
a Build 37
b OR per minor allele, adjusted for age, study and nine European principal components
Table 3 Associations with overall breast cancer risk for seven independent imputed SNPs at STAT3 in women of European ancestry
SNP Chr. Positiona Counted
allele
AFb Cases Controls Single SNP analysis Conditional analysisd
OR (95 % CI)c p value OR (95 %CI)c p value
rs8074296 17 40,583,421 G 0.336 42,510 40,577 1.05 (1.03–1.08) 8.6 9 10-7 1.05 (1.03–1.07) 2.3 9 10-5
rs146170568 17 40,517,716 T 0.005 42,510 40,577 1.32 (1.16–1.50) 2.1 9 10-5 1.27 (1.11–1.44) 3.2 9 10-4
rs141732716 17 40,469,832 A 0.005 42,510 40,577 1.38 (1.14–1.68) 0.001 1.33 (1.09–1.62) 0.004
rs138391971 17 40,505,106 G 0.003 42,510 40,577 0.60 (0.43–0.83) 0.002 0.61 (0.44–0.85) 0.003
rs12952342 17 40,553,640 G 0.119 42,510 40,577 1.07 (1.03–1.12) 0.002 1.07 (1.02–1.11) 0.005
rs190765034 17 40,428,622 G 0.026 42,510 40,577 1.14 (1.03–1.25) 0.010 1.17 (1.06–1.29) 0.002
rs190137766 17 40,422,371 T 0.002 42,510 40,577 0.68 (0.50–0.94) 0.018 0.66 (0.48–0.90) 0.009
SNP single nucleotide polymorphism, Chr. chromosome, OR odds ratio, CI confidence interval, STAT3 signal transducer and activator of
transcription 3
a Build 37
b Allele frequency (AF) of counted allele
c OR per counted allele, adjusted for age, study and 16 European principal components
d Each SNP was tested adjusting for rs8074296, age, study and 16 European principal components. Estimate for rs8074296 is based on model
including rs146170568
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and 0.07, respectively) while all other variants in Table 4
were at least in moderate LD with rs8074296 (r2 C 0.46,
Online Resource 6). The LD plot (Online Resource 6) also
shows that chr17:40607850:I and rs77942990 are in high
LD (r2 = 0.83). A regional association plot for the geno-
typed SNP rs1905339 and all 885 imputed SNPs with-
in ±50 kb of STAT3 and PTRF included in this analysis is
shown in Fig. 2. Associations of SNPs shown in Table 3 as
well as associations of chr17:40607850:I and rs77942990
with breast cancer risk were not significantly heteroge-
neous between studies (all p values for heterogeneity
[0.1); forest plots can be found in Online Resource 7 to
16.
Gene-level and pathway associations
Gene-level associations with risks of overall breast cancer,
ER-positive and ER-negative diseases, respectively, for the
133 candidate genes in the immunosuppression pathway
are summarized in Online Resource 17. TGFBR2 and
CCND1 showed significant associations with overall breast
cancer risk (p value\10-6 and 3.0 9 10-4, respectively).
In addition, IL5 and GM-CSF may be further potential
susceptibility loci of breast cancer (p value = 1.0 9 10-3
and 7.0 9 10-3, respectively). STAT3 showed a less sig-
nificant association with overall breast cancer risk
(p value = 0.033). The immunosuppression pathway as a
whole yielded a significant association with overall breast
cancer risk (p value\10-6). Similar gene-level and path-
way associations were found for ER-positive but not for
ER-negative breast cancer (Online Resource 17). We found
significant enrichment of association in the immunosup-
pression pathway based on the results of the single SNPs
association analyses (313 of 3595 tests significant at
a = 0.05, exact binomial test p value = 2.2 9 10-16).
Haplotype analyses
Despite the evidence for a possible role of IL5 and GM-
CSF in breast cancer susceptibility from the gene-level
analysis, no individual SNPs at IL5 or GM-CSF yielded
significant genetic associations. To identify potential sus-
ceptibility haplotypes, haplotype-specific associations were
assessed based on seven SNPs in or near IL5 (rs4143832,
rs2079103, rs2706399, rs743562, rs739719, rs2069812 and
rs2244012) and nine SNPs in or near GM-CSF
(rs11575022, rs2069616, rs25881, rs25882, rs25883,
rs27349, rs27438, rs40401 and rs743564). The LD struc-
tures for these SNPs at IL5 and GM-CSF are shown in
Online Resource 18 and 19, respectively. In our study
sample of women of European ancestry, 11 and 7 common
haplotypes with frequency[1 % were observed at IL5 and
GM-CSF, respectively. The haplotype AAAACGG in IL5
was associated with a decreased overall breast cancer risk
(OR 0.96, 95 % CI 0.93–0.99, p value = 5.0 9 10-3,
Table 5). In GM-CSF, the haplotype AAGAGCGAA was
Fig. 1 Linkage disequilibrium
plot showing r2 values and color
schemes for the genotyped SNP
rs1905339 and seven
independent imputed SNPs as
well as imputed SNP
rs181888151 within ±50 kb of
STAT3. The linkage
disequilibrium (LD) plot shows
that SNP rs1905339 is in strong
LD with the imputed SNP
rs8074296 (r2 = 0.99), and
independent of the other six
imputed SNPs (r2 B 0.01) at
STAT3. LD was estimated based
on control data
144 Hum Genet (2016) 135:137–154
123
Table 4 Associations with overall breast cancer risk for 19 imputed variants near PTRF in women of European ancestry
SNP Chr Positiona Counted
allele
AFb Cases Controls Single SNP analysis Conditional analysisd
ORc (95 % CI) p value ORc (95 % CI) p value
rs8074296 17 40,583,421 G 0.336 42,510 40,577 1.05 (1.03–1.08) 8.6 9 10-7 1.04 (1.02–1.06) 0.0006
rs1032070 17 40,618,251 T 0.269 42,510 40,577 1.06 (1.04–1.09) 1.5 9 10-7 1.04 (1.00–1.09) 0.0359
rs34460267 17 40,615,865 C 0.269 42,510 40,577 1.06 (1.04.1.09) 1.9 9 10-7 1.04 (1.00–1.09) 0.0424
rs34807589 17 40,624,656 T 0.264 42,510 40,577 1.06 (1.04–1.09) 2.0 9 10-7 1.04 (1.00–1.09) 0.0423
rs36005199 17 40,597,555 G 0.268 42,510 40,577 1.06 (1.04–1.09) 2.1 9 10-7 1.04 (1.00–1.09) 0.0490
rs12603201 17 40,595,927 T 0.581 42,510 40,577 0.95 (0.93–0.97) 3.1 9 10-7 0.97 (0.93–1.00) 0.0662
chr17:40607850:I 17 40,607,850 CT 0.055 42,510 40,577 1.13 (1.07–1.18) 7.0 9 10-7 1.09 (1.04–1.15) 0.0005
rs4796662 17 40,594,882 C 0.576 42,510 40,577 0.95 (0.93–0.97) 1.8 9 10-6 0.98 (0.94–1.01) 0.2217
rs34349578 17 40,598,129 A 0.195 42,510 40,577 1.07 (1.04–1.10) 2.1 9 10-6 1.04 (1.00–1.08) 0.0809
rs62075801 17 40,593,921 T 0.576 42,510 40,577 0.95 (0.93–0.97) 2.1 9 10-6 0.98 (0.94–1.01) 0.2385
rs12951640 17 40,594,298 A 0.253 42,510 40,577 1.06 (1.03–1.08) 2.1 9 10-6 1.03 (0.98–1.07) 0.2269
rs77942990 17 40,622,538 A 0.046 42,510 40,577 1.13 (1.07–1.19) 2.2 9 10-6 1.09 (1.04–1.15) 0.0007
rs35111218 17 40,595,572 T 0.252 42,510 40,577 1.06 (1.03–1.08) 2.3 9 10-6 1.03 (0.98–1.07) 0.2311
rs6503704 17 40,592,253 A 0.253 42,510 40,577 1.06 (1.03–1.08) 2.3 9 10-6 1.03 (0.98–1.07) 0.2413
rs12943498 17 40,593,901 C 0.253 42,510 40,577 1.06 (1.03–1.08) 2.5 9 10-6 1.02 (0.98–1.07) 0.2529
rs12951549 17 40,593,502 T 0.253 42,510 40,577 1.06 (1.03–1.08) 2.6 9 10-6 1.02 (0.98–1.07) 0.2537
chr17:40593802:I 17 40,593,802 GTTTC 0.251 42,510 40,577 1.06 (1.03–1.08) 3.5 9 10-6 1.02 (0.98–1.07) 0.2943
rs6503703 17 40,592,207 T 0.261 42,510 40,577 1.06 (1.03–1.08) 6.5 9 10-6 1.02 (0.98–1.06) 0.3775
chr17:40595896:D 17 40,595,896 C 0.211 42,510 40,577 1.06 (1.03–1.09) 9.0 9 10-6 1.02 (0.98–1.07) 0.2373
SNP single nucleotide polymorphism, Chr. chromosome, OR odds ratio, CI confidence interval, STAT3 signal transducer and activator of
transcription 3
a Build 37
b Allele frequency (AF) of counted allele
c OR per counted allele, adjusted for age, study and 16 European principal components
d Each SNP was tested adjusting for rs8074296, age, study and 16 European principal components. Estimate for rs8074296 was based on model
including chr17:40607850:I
Fig. 2 Regional association
plot for the genotyped SNP
rs1905339 and 885 imputed
SNPs within ±50 kb of STAT3
and PTRF. Each dot represents
an SNP. The color of each dot
reflects the extent of linkage
disequilibrium (r2) with SNP
rs1032070 (in purple diamond).
Genomic positions of SNPs
were plotted based on hg19/
1000 Genomes Mar 2012
European. Association is
represented at the -log10 scale.
cM/Mb centiMorgans/megabase
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also associated with a decreased overall breast cancer risk
(OR 0.92, 95 % CI 0.87–0.96, p value = 2.7 9 10-4,
Table 6). The global p value for haplotype association was
significant for both IL5 (p value = 0.005) and GM-CSF
(p value = 0.007).
Gene expression analyses
Using TCGA RNA sequencing level 3 data, we found that
RNA expression levels of STAT3 and IL5 were signifi-
cantly higher in 113 normal tissue samples compared to
989 breast tumor samples (p value = 1.3 9 10-3 and
7.0 9 10-4, respectively, Online Resources 20 and 21),
while overall expression of IL5 was low in both tissues.
Also expression levels of PTRF were significantly higher
in normal tissue compared to tumor tissue samples
(p value B0.0001, Online Resource 22). GM-CSF expres-
sion was very low and did not differ between breast tumor
samples and normal tissue samples (p value = 0.49,
Online Resource 23). Among 183 mammary tissues in the
GTEx database, SNPs rs1905339, rs8074296 and
rs77942990 were not significantly correlated with STAT3
(p values = 0.36, 0.36, and 0.2, respectively; Online
Resource 24 to 26) or PTRF expression (p values = 0.4,
0.4, and 0.39 Online Resource 27 to 29). The SNPs
rs1905339 and rs8074296 were significant eQTL for
TUBG2 (both p values = 9.9 9 10-7, Online Resource 30
and 31). The STAT3/PTRF variants rs146170568 and
chr17:40607850:I were not available in the GTEx
database.
Discussion
Our comprehensive examination of associations between
polymorphisms in the immunosuppression pathway genes
and breast cancer risk revealed that STAT3, IL5, and GM-
CSF may play a role in overall breast cancer susceptibility
among women of European ancestry.
The in silico functional analysis revealed that within a
±50 kb window of STAT3, several polymorphisms are
located in regulatory regions that could actively affect
DNA transcription (Fig. 3). The SNP rs181888151, which
is in complete LD with rs146170568 (r2 = 1) but inde-
pendent of rs1905339 (r2 = 0.01, Fig. 1) was significantly
associated with increased risk for overall breast cancer
(per allele OR 1.31, 95 % CI 1.16–1.49, p value =
2.8 9 10-5). Together with a further independently asso-
ciated imputed SNP rs141732716, these polymorphisms
reside in strong DNase I hypersensitivity and transcription
regulatory sites (Fig. 3). This suggests that they may be
functional polymorphisms, but further experimental work
is required for confirmation.T
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STAT3 encodes the signal transducer and activator of
transcription 3, which is a member of the STAT protein
family. Activated by corresponding cytokines or growth
factors, STAT3 can be phosphorylated and translocate into
the cell nucleus, acting as a transcription activator. In
addition, STAT3 plays a key role in regulating immune
response in the tumor microenvironment (Yu et al. 2009).
STAT3 signaling is required for immunosuppressive and
tumor-promoting functions of MDSCs (Cheng et al. 2003,
2008; Kortylewski et al. 2005, 2009; Kujawski et al. 2008;
Ostrand-Rosenberg and Sinha 2009; Yu et al. 2009), as
well as for Treg cell expansion (Kortylewski et al. 2005,
2009; Matsumura et al. 2007). STAT3 has been reported in
several previous genome-wide association studies (GWAS)
to be associated with immune relevant diseases such as
Crohn’s disease (Barrett et al. 2008; Franke et al. 2008;
Yamazaki et al. 2013), inflammatory bowel disease (Jos-
tins et al. 2012), and multiple sclerosis (Jakkula et al. 2010;
Patsopoulos et al. 2011; Sawcer et al. 2011). Additionally,
expression of STAT3 was suggested to be enriched in tri-
ple-negative breast cancer, and negatively associated with
lymph node involvement and breast tumor stage in a study
based on an in silico network approach (Liu et al. 2012b).
However, the association of rs1905339 with triple-negative
breast cancer risk in our study (N triple-negative breast
cancer = 2600) was similar and not stronger compared to
the association observed for overall breast cancer risk (per
allele OR 1.06, 95 % CI 0.99–1.14, p value = 0.11).
The genotyped SNP rs1905339 is also located at 7 kb 50
of PTRF, which encodes the polymerase I and transcript
release factor, and is not known to be directly involved in
immunosuppression. In addition, two independently associ-
ated imputed SNPs rs8074296 and rs12952342 (r2 = 0.99
and 0 with rs1905339, respectively, Fig. 1) are located at
8 kb 50 and 0.8 kb 30 of PTRF, respectively (Fig. 3). PTRF is
known to contribute to the formation of caveolae, small
membrane caves involved in cell signaling, lipid regulation,
and endocytosis (Chadda and Mayor 2008). Recently, down-
regulation of PTRF was observed in breast cancer cell lines
and breast tumor tissue, suggesting that PTRF expression
might be an indicator for breast cancer progression (Bai et al.
2012). The SNPs rs1905339 and rs8074296 were also found
to be eQTL for TUBG2 (tubulin, gamma 2) in the GTEx
database, the expression of TUBG2 decreased with each
variant allele (Online Resources 30 and 31, respectively).
TUBG2 encodes c-tubulin, a protein required for the for-
mation and polar orientation of microtubules in cells. It is
currently unknown, whether TUBG2 plays a role in breast
cancer development or progression.
The other two potential susceptibility loci, IL5 and GM-
CSF, are both located in a known cytokine gene cluster at
5q31. IL5 encodes interleukin 5, a cytokine secreted by
CD4? T helper 2 cells (Mills 2004; Parker 1993). IL5 is aT
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growth and differentiation factor for both B cells and
eosinophils, triggering eosinophil- and B cell-dependent
immune response (Mills 2004; Parker 1993). GM-CSF
encodes granulocyte–macrophage colony stimulating fac-
tor, a cytokine that controls differentiation and function of
granulocytes and macrophages. GM-CSF is also a MDSC-
inducing and activating factor in the bone marrow (Os-
trand-Rosenberg and Sinha 2009; Serafini et al. 2004). In
the tumor microenvironment, GM-CSF is the cytokine for
dendritic cell differentiation and function, and it is often
found to be underexpressed (Zou 2005). Additionally, 5q31
has been found to be a susceptibility locus for rheumatoid
arthritis (Okada et al. 2012, 2014) and inflammatory bowel
disease (Jostins et al. 2012).
Immunosuppression is a complex network with plenty
of contributors, including transcription factors (e.g.,
STAT3), as well as immune mediating cytokines (e.g., IL5
and GM-CSF). Results of this analysis indicate that genetic
variation in different components of the immunosuppres-
sion pathway may be susceptibility loci of breast cancer
among women of European ancestry.
The main strengths of the present analysis were its large
sample size, the uniform genotyping procedures and cen-
tralized quality controls used. The imputation of genotypes
in the most interesting susceptibility loci provided an
opportunity to identify more strongly associated variants.
Assessments of gene-level associations also provided evi-
dence for additional putative susceptibility loci. A limita-
tion was the lack of an independent sample to replicate the
observed associations; this will be feasible in the future
using new studies participating in the BCAC. Further
functional studies are still needed to identify causal variants
and to investigate the underlying biological mechanisms.
Conclusions
Overall, our data provide strong evidence that common
variation in the immunosuppression pathway is associated
with breast cancer susceptibility. The strongest candidates
for mediating this association were STAT3, IL5, and GM-
CSF, but we cannot exclude the possibility of multiple
alleles each with effects too small to confirm.
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